title: Evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Gene Status in Human Breast Cancer Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens by Fluorescence In Situ Hybridization (FISH).
abstract: Current standard of care requires that HER2 gene testing be performed on all newly diagnosed invasive breast cancers in order to determine eligibility for anti-HER2 antibody therapy and should be performed in accordance with current ASCO-CAP guidelines (Hammond et al., J Clin Oncol 29(15):e458, 2011; Wolff et al., J Clin Oncol 31(31):3997-4013, 2013). Here we describe a HER2 FISH methodology to evaluate HER2 gene status in FFPE breast tumor specimens.
authors.affiliation: Department of Molecular Pathology, PhenoPath Laboratories, 551 North 34th Street, Seattle, WA, 98103-8675, USA. hhwang@phenopath.com.
authors.forename: Harry C
authors.initials: HC
authors.lastname: Hwang
authors.affiliation: Department of Molecular Pathology, PhenoPath Laboratories, 551 North 34th Street, Seattle, WA, 98103-8675, USA.
authors.forename: Allen M
authors.initials: AM
authors.lastname: Gown
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D045744:Cell Line, Tumor; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D010232:Paraffin; D016612:Paraffin Embedding; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D016707:Tissue Fixation
chemical_list: D010232:Paraffin; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Breast cancer; DNA probe; FISH; Fluorescence in situ hybridization; HER2; Herceptin; Human epidermal growth factor receptor 2; PathVysion